Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05937958

MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible (MARGARITA)

The goal of this observational study is to explore the effectiveness and side effects of a high dose daily adapted SBRT (stereotactic body radiotherapy) boost delivered with MRLinac in patients with gynaecological cancers that cannot receive a brachytherapy boost to the primary tumour for different reasons (medical conditions, tumour extensions, etc). Current alternative for brachytherapy in these situations is often a non-adaptive conebeam- CT guided boost. Conebeam-CT guided non-adaptive high dose SBRT in under these circumstances is described being quite toxic.

The main questions this study aims to answer are:

* In how many cases could local control (i.e. total disappearance of the tumor) is be achieved with this treatment? * Which side effects are observed in patients receiving this treatment?

Participants will be asked to fill out questionnaires (e.g. regarding side effects). Furthermore, participants are asked if their clinical data may be used for study purposes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cervical Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gynecologic Cancer Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Odense University Hospital, Odense, Denmark

Loading trial locations.

About this study

Standard treatment of locally advanced cervical cancer is chemoradiotherapy (external beam radiotherapy (EBRT) and concomitant chemotherapy with weekly Cisplatin) followed by image guided brachytherapy (IGBT). Recently, the MR Linac has emerged as new option for delivering an external beam radiotherapy boost to the primary cervical tumour after (chemo)radiaton in case brachytherapy is not feasible. MR Linac in these cases can replace traditional EBRT boosts and allow for better visualisation of the anatomy, smaller treatment margins and online treatment planning adaptation. This comes with potential for higher dose to the target and less dose to the surrounding organs.

Like in IGBT, an MRL treatment provides the possibility to perform repetitive imaging before and even during each fraction and allows for dose adaptation to anatomical changes in individual patients. This way not not only the daily position of OARs in relation to the target can be taken into account, but also possible tumor regression which often is obtained during chemoradiation. Based on the experience collected so far, the MRL treatment may be an interesting treatment option in selected cases as daily MRI and plan adaptation leads to more confined dose distribution compared to CBCT-Linac options. However, dose levels for the MRL-boost are likely to be lower than for IGBT, therefore its effectiveness is still unsure.

Aims of the study:

  • To introduce MRL-boost in locally advanced cervical cancer in a multicenter setting within the frame of a prospective observational study.
  • To establish a bench-mark for clinical outcome with MRL-boost in a multi-center patient population with respect to local control, survival and toxicity.
  • To establish reference material with regard to MRL-based DVH parameters; if applicable delineations according to the guidelines from the GEC-ESTRO gynecology working group will be used.
  • To report image-based DVH parameters for target (GTV, CTV, PTV) and for OARs
  • To report recurrence patterns
  • To report Quality of Life

Type of design

This study is a multicenter prospective observational study. Patient registration and dosimetric reporting will be performed in the individual centers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with newly biopsy proven advanced stage gynecological cancers (excluding ovarian cancers) and endometrium in whom definitive (chemo)radiotherapy with curative intent is planned are qualified for the study, as well as, patients with recurrent gynecological cancers (excluding ovarian cancers) for which no prior (chemo)radiation was performed for which (chemo)radiotherapy with curative intent is planned.
  • Patients with para-aortic metastatic nodes (stage IVB) to the level of L2 are also eligible but patients with further dissemination are not.
  • Staging according to FIGO (2018, https://doi.org/10.1002/ijgo.12611) and TNM (version 9, 2021, https://doi.org/10.3322/caac.21663) staging.
  • Patients who gave informed consent to take part in the MOMENTUM study (NCT04075305) to use their clinical data for publication and share their data with other (European) sites.

Exclusion criteria

  • Hard contra-indication for MRI scanning

Treatment and study plan

Primary outcomes

  1. Local control

    Time frame: 3 months after MRLinac treatment

    Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

  2. Local control

    Time frame: 6 months after MRLinac treatment

    Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

  3. Local control

    Time frame: 12 months after MRLinac treatment

    Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

  4. Local control

    Time frame: 24 months after MRLinac treatment

    Local control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

Secondary outcomes

  1. Regional control

    Time frame: 3 months after MRLinac treatment

    Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

  2. Regional control

    Time frame: 6 months after MRLinac treatment

    Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

  3. Regional control

    Time frame: 12 months after MRLinac treatment

    Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

  4. Regional control

    Time frame: 24 months after MRLinac treatment

    Regional control of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

  5. Distant failure

    Time frame: 3 months after MRLinac treatment

    Distant failure of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care

  6. Distant failure

    Time frame: 12 months after MRLinac treatment

    Distant failure of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care

  7. Distant failure

    Time frame: 24 months after MRLinac treatment

    Distant failure of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care

  8. Gastrointestinal toxicity

    Time frame: 3 months after MRLinac treatment

    Gastrointestinal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  9. Gastrointestinal toxicity

    Time frame: 6 months after MRLinac treatment

    Gastrointestinal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  10. Gastrointestinal toxicity

    Time frame: 24 months after MRLinac treatment

    Gastrointestinal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  11. Urogenital toxicity

    Time frame: 3 months after MRLinac treatment

    Urogenital toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  12. Urogenital toxicity

    Time frame: 6 months after MRLinac treatment

    Urogenital toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  13. Urogenital toxicity

    Time frame: 24 months after MRLinac treatment

    Urogenital toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  14. Vaginal toxicity

    Time frame: 3 months after MRLinac treatment

    Vaginal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  15. Vaginal toxicity

    Time frame: 6 months after MRLinac treatment

    Vaginal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

  16. Vaginal toxicity

    Time frame: 24 months after MRLinac treatment

    Vaginal toxicity of participating patients will be obtained from the hospital information systems. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary. Patient recorded outcome is (tumor specific) questionaires. See MOMENTUM study (NCT04075305)

Study contacts

Contact information is provided by the study sponsor or research team.

van Lier, PhD

CONTACT

[email protected]

+31 88 755 8800

Sponsors and collaborators

Lead sponsor

UMC Utrecht

Other

Collaborators

  • Odense University Hospital

Registry information

Official study title

MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible

Acronym: MARGARITA

Important dates

Study start
2023
Primary completion
2025
Study completion
2027
First posted
Jul 10, 2023
Registry last updated
Jul 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.